Achieving high uptake of human papillomavirus vaccine in Cameroon: Lessons learned in overcoming challenges

• Published in: Vaccine 2014-07, Vol.32 (35), p.4399-4403
• Main Authors: Ogembo, Javier Gordon, Manga, Simon, Nulah, Kathleen, Foglabenchi, Lily H, Perlman, Stacey, Wamai, Richard G, Welty, Thomas, Welty, Edith, Tih, Pius
• Format: Article
• Language: English
• Subjects: Acceptability; Adolescent; Adult; Age; Allergy and Immunology; Applied microbiology; Biological and medical sciences; Brochures; Cameroon; Cancer; Cancer vaccines; Cervical cancer; Cervix; Child; Dosage; Education; Feasibility; Female; Fundamental and applied biological sciences. Psychology; Health Education; Health facilities; Human papillomavirus; Humans; Immunization; Medical sciences; Microbiology; Miscellaneous; Multimedia; Nurses; Papillomavirus Infections - immunology; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - administration & dosage; Papillomavirus Vaccines - immunology; Pregnancy; Schools; Tumors; Vaccination; Vaccination - statistics & numerical data; Vaccine; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Virology; Womens health; Young Adult
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2014.06.064

Abstract Background Cameroon has the highest age-standardized incidence rate of cervical cancer (30/100,000 women) in Central Africa. In 2010–2011, the Cameroon Baptist Convention Health Services (CBCHS) received donated human papillomavirus (HPV) vaccine, Gardasil, from Merck & Co. Inc. through Axios Healthcare Development to immunize 6400 girls aged 9–13 years. The aim was to inform the Cameroon Ministry of Health (MOH) of the acceptability, feasibility, and optimal delivery strategies for HPV vaccine. Methods and findings Following approval by the MOH, CBCHS nurses educated girls, parents, and communities about HPV, cervical cancer, and HPV vaccine through multimedia coverage, brochures, posters, and presentations. Because educators were initially reluctant to allow immunization in schools, due to fear of adverse events, the nurses performed 40.7% of vaccinations in the clinics, 34.5% in community venues, and only 24.7% in schools. When no adverse events were reported, more schools and communities permitted HPV vaccine immunization on their premises. To recover administrative costs, CBCHS charged a fee of US$8 per 3-dose series only to those who were able to pay. Despite the fee, 84.6% of the 6,851 girls who received the first dose received all three doses. Conclusions and lessons learned With adequate education of all stakeholders, HPV vaccination is acceptable and feasible in Cameroon. Following this demonstration project, in 2014 the Global Access to Vaccines and Immunization (GAVI) Alliance awarded the Cameroon MOH HPV vaccine at a price of US$4.50 per dose to immunize sixth grade girls and girls aged 10 years who are not in school in two districts of Cameroon.